Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharm ; 9(10): 2894-902, 2012 Oct 01.
Article in English | MEDLINE | ID: mdl-22957849

ABSTRACT

Ribonucleases are promising agents for use in anticancer therapy. Engineering a nuclear localization signal into the sequence of the human pancreatic ribonuclease has been revealed as a new strategy to endow this enzyme with cytotoxic activity against tumor cells. We previously described a cytotoxic human pancreatic ribonuclease variant, named PE5, which is able to cleave nuclear RNA, inducing the apoptosis of cancer cells and reducing the amount of P-glycoprotein in different multidrug-resistant cell lines. These results open the opportunity to use this ribonuclease in combination with other chemotherapeutics. In this work, we have investigated how to improve the properties of PE5 as an antitumor drug candidate. When attempting to develop a recombinant protein as a drug, two of the main desirable attributes are minimum immunogenicity and maximum potency. The improvements of PE5 have been designed in both senses. First, in order to reduce the potential immunogenicity of the protein, we have studied which residues mutated on PE5 can be reverted to those of the wild-type human pancreatic ribonuclease sequence without affecting its cytotoxicity. Second, we have investigated the effect of introducing an additional nuclear localization signal at different sites of PE5 in an effort to obtain a more cytotoxic enzyme. We show that the nuclear localization signal location is critical for the cytotoxicity. One of these variants, named NLSPE5, presents about a 10-fold increase in cytotoxicity respective to PE5. This variant induces apoptosis and kills the cells using the same mechanism as PE5.


Subject(s)
Cell Nucleus/metabolism , Nuclear Localization Signals/biosynthesis , Nuclear Localization Signals/genetics , Ribonuclease, Pancreatic/biosynthesis , Ribonuclease, Pancreatic/genetics , Antineoplastic Agents/metabolism , Apoptosis/drug effects , Apoptosis/genetics , Cell Line, Tumor , Cell Nucleus/genetics , HeLa Cells , Humans , Jurkat Cells , Mutation , Nuclear Localization Signals/administration & dosage , Nuclear Localization Signals/metabolism , RNA, Nuclear/genetics , RNA, Nuclear/metabolism , Recombinant Proteins/administration & dosage , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Ribonuclease, Pancreatic/administration & dosage , Ribonuclease, Pancreatic/metabolism
2.
Biophys J ; 101(2): 459-67, 2011 Jul 20.
Article in English | MEDLINE | ID: mdl-21767499

ABSTRACT

The structural determinants that are responsible for the formation of higher order associations of folded proteins remain unknown. We have investigated the role on the dimerization process of different residues of a domain-swapped dimer human pancreatic ribonuclease variant. This variant is a good model to study the dimerization and swapping processes because dimer and monomer forms interconvert, are easily isolated, and only one dimeric species is produced. Thus, simple models for the swapping process can be proposed. The dimerization (dissociation constant) and swapping propensity have been studied using different variants with changes in residues that belong to different putative molecular determinants of dimerization. Using NMR spectroscopy, we show that these mutations do not substantially alter the overall conformation and flexibility, but affect the residue level stability. Overall, the most critical residues for the swapping process are those of one subunit that interact with the hinge loop of another one-subunit residue, stabilizing it in a conformation that favors the interchange. Tyr(25), Gln(101), and Pro(19), with Asn(17), Ser(21), and Ser(23), are found to be the most significant; notably, Glu(103) and Arg(104), which were postulated to form salt bridges that would stabilize the dimer, are not critical for dimerization.


Subject(s)
Mutant Proteins/chemistry , Mutant Proteins/metabolism , Ribonuclease, Pancreatic/chemistry , Ribonuclease, Pancreatic/metabolism , Amino Acids/metabolism , Enzyme Stability , Humans , Kinetics , Magnetic Resonance Spectroscopy , Protein Binding , Protein Multimerization , Protein Structure, Secondary , Protein Structure, Tertiary , Protein Subunits/chemistry , Protein Subunits/metabolism , Thermodynamics
3.
Invest New Drugs ; 29(5): 811-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-20352290

ABSTRACT

We have previously described a human pancreatic-ribonuclease variant, named PE5, which carries a non-contiguous extended bipartite nuclear localization signal. This signal comprises residues from at least three regions of the protein. We postulated that the introduction of this signal in the ribonuclease provides it with cytotoxic activity because although the variant poorly evades the ribonuclease inhibitor in vitro, it is routed to the nucleus, which is devoid of the inhibitor. In this work, we have investigated the relationship between the cytotoxicity produced by PE5 and its ability to reach the nucleus. First, we show that this enzyme, when incubated with HeLa cells, specifically cleaves nuclear RNA while it leaves cytoplasmic RNA unaffected. On the other hand, we have created new variants in which the residues of the nuclear localization signal that are important for the nuclear transport have been replaced. As expected, the individual changes produce a significant decrease in the cytotoxicity of the resulting variants. We conclude that the nuclear transport of PE5 is critical for its cytotoxicity. Therefore, routing a ribonuclease to the nucleus is an alternative strategy to endow it with cytotoxic activity.


Subject(s)
Cell Nucleus/enzymology , Mutant Proteins/metabolism , Ribonuclease, Pancreatic/metabolism , Active Transport, Cell Nucleus , Amino Acids/metabolism , Cell Death , HeLa Cells , Humans , RNA/metabolism , Substrate Specificity , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL